Emma Hudson
About
Emma Hudson is a scholar working on Obstetrics and Gynecology, Surgery and Molecular Biology.
According to data from OpenAlex, Emma Hudson has authored 30 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Obstetrics and Gynecology, 10 papers in Surgery and 9 papers in Molecular Biology. Recurrent topics in Emma Hudson's work include Endometrial and Cervical Cancer Treatments (11 papers), Pancreatic function and diabetes (6 papers) and Metabolism, Diabetes, and Cancer (5 papers). Emma Hudson is often cited by papers focused on Endometrial and Cervical Cancer Treatments (11 papers), Pancreatic function and diabetes (6 papers) and Metabolism, Diabetes, and Cancer (5 papers). Emma Hudson collaborates with scholars based in United Kingdom, Japan and United States. Emma Hudson's co-authors include D. Grahame Hardie, David Pan, John W. Scott, Stephen M. Downs, Tatsuo Terashima, John M. Lucocq, Kevin A. Green, John James, Simon A. Hawley and Otto Baba and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Hepatology.
In The Last Decade
Emma Hudson
27 papers receiving 1.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Emma Hudson United Kingdom | 14 | 1.1k | 574 | 311 | 249 | 173 | 30 | 1.7k | ||
| Robert Augustin Germany | 25 | 982 0.9× | 431 0.8× | 376 1.2× | 222 0.9× | 620 3.6× | 36 | 2.1k | ||
| Sophie Brûlé Canada | 10 | 1.3k 1.2× | 388 0.7× | 436 1.4× | 285 1.1× | 167 1.0× | 11 | 1.8k | ||
| Amelia K. Linnemann United States | 23 | 817 0.8× | 497 0.9× | 236 0.8× | 270 1.1× | 265 1.5× | 43 | 1.7k | ||
| Guoli Dai United States | 25 | 905 0.8× | 179 0.3× | 207 0.7× | 244 1.0× | 275 1.6× | 62 | 2.0k | ||
| Mats Gåfvels Sweden | 26 | 873 0.8× | 835 1.5× | 223 0.7× | 349 1.4× | 348 2.0× | 69 | 2.5k | ||
| Juan Carlos Calvo Argentina | 22 | 570 0.5× | 105 0.2× | 410 1.3× | 412 1.7× | 235 1.4× | 79 | 2.0k | ||
| Ying Du China | 22 | 746 0.7× | 234 0.4× | 321 1.0× | 307 1.2× | 142 0.8× | 50 | 1.5k | ||
| Thomas Bouckenooghe Belgium | 17 | 502 0.5× | 811 1.4× | 288 0.9× | 131 0.5× | 436 2.5× | 28 | 1.9k | ||
| Ingrid C. Gaemers Netherlands | 20 | 780 0.7× | 179 0.3× | 157 0.5× | 277 1.1× | 180 1.0× | 33 | 1.5k | ||
| Luca Ulianich Italy | 27 | 642 0.6× | 138 0.2× | 228 0.7× | 255 1.0× | 314 1.8× | 42 | 1.5k |
Countries citing papers authored by Emma Hudson
Since
Specialization
Citations
This map shows the geographic impact of Emma Hudson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emma Hudson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emma Hudson more than expected).
Fields of papers citing papers by Emma Hudson
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Emma Hudson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emma Hudson. The network helps show where Emma Hudson may publish in the future.
Co-authorship network of co-authors of Emma Hudson
This figure shows the co-authorship network connecting the top 25 collaborators of Emma Hudson. A scholar is included among the top collaborators of Emma Hudson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emma Hudson. Emma Hudson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Towler, Mhairi C., Emma Hudson, Thomas Macartney, et al.. (2024). AMPK associates with and causes fragmentation of the Golgi by phosphorylating the guanine nucleotide exchange factor GBF1. Journal of Cell Science. 137(24).
2.
Sy, Aminata, Emma Hudson, M. Azim Ansari, et al.. (2023). Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus. PLoS ONE. 18(1). e0280551–e0280551.
3.
McCormack, Mary, Gemma Eminowicz, Patricia Díez, et al.. (2023). LBA8 A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: The GCIG INTERLACE trial. Annals of Oncology. 34. S1276–S1276.
4.
Slomovitz, Brian M., David Cibula, Tayup Şimşek, et al.. (2022). KEYNOTE-C93/GOG-3064/ENGOT-en15: A phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma.. Journal of Clinical Oncology. 40(16_suppl). TPS5623–TPS5623.
5.
Smith, David A., Daniel Bradshaw, Jean L. Mbisa, et al.. (2021). Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy. Journal of Viral Hepatitis. 28(9). 1256–1264.
6.
Lester, J.F., Carles Escriu, Sarah Khan, et al.. (2021). Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom. BMC Cancer. 21(1). 515–515.
7.
Colombo, Nicoletta, Yoland Antill, M.P. Barretina Ginesta, et al.. (2020). 884TiP AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer. Annals of Oncology. 31. S647–S647.
8.
Smith, David A., Daniel Bradshaw, Jean L. Mbisa, et al.. (2020). Real-world retreatment of HCV-infected patients with prior failure to direct acting antiviral therapy using sofosbuvir, velpatasvir and voxilaprevir. Journal of Hepatology. 73. S336–S336.
9.
Lord, Rosemary, Tamsin Morris, Rachel Jones, et al.. (2020). Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors. International Journal of Gynecological Cancer. 30(7). 1026–1033.
10.
Ramamurthy, Narayan, Emanuele Marchi, M. Azim Ansari, et al.. (2018). Impact of Interferon Lambda 4 Genotype on Interferon‐Stimulated Gene Expression During Direct‐Acting Antiviral Therapy for Hepatitis C. Hepatology. 68(3). 859–871.
11.
Howells, R. E., et al.. (2014). Why Routine Clinical Follow-up for Patients With Early Stage Endometrial Cancer Is Not Always Necessary. International Journal of Gynecological Cancer. 24(3). 556–563.
12.
Kranzer, Katharina, L. Karl Olson, Nienke van Schaik, et al.. (2011). Quality of induced sputum using a human-powered nebuliser in a mobile human immunodeficiency virus testing service in South Africa. The International Journal of Tuberculosis and Lung Disease. 15(8). 1077–1081.
13.
Hudson, Emma, Chris Hurt, D. Mort, et al.. (2009). Induction Chemotherapy Followed by Chemoradiation in Locally Advanced Pancreatic Cancer: an Effective and Well-tolerated Treatment. Clinical Oncology. 22(1). 27–35.
14.
Hudson, Emma & J.F. Lester. (2009). Gemcitabine and carboplatin in the treatment of transitional cell carcinoma of the urothelium: a single centre experience and review of the literature. European Journal of Cancer Care. 19(3). 324–328.
15.
Chen, Jing, Emma Hudson, M. Maggie, et al.. (2006). AMPK regulation of mouse oocyte meiotic resumption in vitro. Developmental Biology. 291(2). 227–238.
16.
Hudson, Emma, David Pan, John James, et al.. (2003). A Novel Domain in AMP-Activated Protein Kinase Causes Glycogen Storage Bodies Similar to Those Seen in Hereditary Cardiac Arrhythmias. Current Biology. 13(10). 861–866.
17.
Downs, Stephen M., Emma Hudson, & D. Grahame Hardie. (2002). A Potential Role for AMP-Activated Protein Kinase in Meiotic Induction in Mouse Oocytes. Developmental Biology. 245(1). 200–212.
18.
Spencer, John, Wee Joo Chng, Emma Hudson, A P Boon, & Peter Whelan. (1998). Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer.. British Journal of Radiology. 71(851). 1130–1135.
19.
Hudson, Emma, Lisha Ma, Colin J. Wilde, David J. Flint, & Stephen A. Baldwin. (1997). Regulation of GLUT1 expression in the mammary gland. Biochemical Society Transactions. 25(3). 464S–464S.
20.
Moghissi, K., Kate Dixon, Emma Hudson, & Mark R. Stringer. (1995). Photodynamic therapy of oesophageal cancer. Lasers in Medical Science. 10(1). 67–71.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Robert Augustin Breakdown of academic impact, for papers by Sophie Brûlé Breakdown of academic impact, for papers by Amelia K. Linnemann Breakdown of academic impact, for papers by Guoli Dai Breakdown of academic impact, for papers by Mats Gåfvels Breakdown of academic impact, for papers by Juan Carlos Calvo Breakdown of academic impact, for papers by Ying Du Breakdown of academic impact, for papers by Thomas Bouckenooghe Breakdown of academic impact, for papers by Ingrid C. Gaemers Breakdown of academic impact, for papers by Luca Ulianich